CUV — Clinuvel Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- AU$720.83m
- AU$547.45m
- AU$82.23m
- 96
- 30
- 27
- 53
Annual income statement for Clinuvel Pharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2019 June 30th | R2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 31.6 | 33.1 | 48.3 | 66.2 | 82.2 |
| Cost of Revenue | |||||
| Gross Profit | — | 32.3 | 50.2 | 64.8 | 89.9 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 14.4 | 20.2 | 19.6 | 30.2 | 34.2 |
| Operating Profit | 17.3 | 12.9 | 28.7 | 36 | 48 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 18.1 | 11.5 | 25.7 | 34.3 | 45.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 18.1 | 15.1 | 24.7 | 20.9 | 30.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 18.1 | 15.1 | 24.7 | 20.9 | 30.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 18.1 | 15.1 | 24.7 | 20.9 | 30.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.366 | 0.311 | 0.5 | 0.414 | 0.607 |
| Dividends per Share |